Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care SettingNuijten, M. J. C., Brignone, M., Marteau, F., den Boer, J. A. & Hoencamp, E., Jun-2012, In : Clinical Therapeutics. 34, 6, p. 1364-1378 15 p.
Research output: Contribution to journal › Article › Academic › peer-review
Objective: This study assessed the cost-effectiveness of escitalopram for the treatment of depression in the Netherlands from a societal perspective.
Methods: A decision tree model was constructed using decision analytical techniques. Data sources included published literature, clinical trials, official price/tariff lists, national population statistics, and Delphi panel data. The comparators were venlafaxine XR and citalopram. The primary perspective of this health economic evaluation was that of the society in the Netherlands in 2010. The time horizon was 26 weeks. The effectiveness outcomes of the study were quality-adjusted life-years (QALYs).
Results: Escitalopram was associated with a cost savings per patient of 263 versus venlafaxine XR and 1992 versus citalopram over a period of 26 weeks from a societal perspective. Escitalopram was also associated with a gains QALYs: 0.0062 versus venlafaxine XR and 0.0166 versus citalopram. Escitalopram was dominant over both venlafaxine XR and citalopram.
Conclusion: Based on the findings from this cost-effectiveness analysis, the favorable clinical benefit of escitalopram resulted in a positive health economic benefit in the Netherlands. (Clin Ther. 2012; 34:1364-1378) (C) 2012 Published by Elsevier HS Journals, Inc.
|Number of pages||15|
|Publication status||Published - Jun-2012|
- cost-effectiveness, escitalopram, Europe, major depressive disorder, the Netherlands, SEROTONIN REUPTAKE INHIBITORS, 1ST-LINE TREATMENT, RECURRENT DEPRESSION, EFFECTIVENESS MODEL, ECONOMIC BURDEN, VS. CITALOPRAM, DOUBLE-BLIND, VENLAFAXINE, DISCONTINUATION, PHARMACOLOGY